Evidence map›Paper›PMID 36798171›Full record

ArticlebioRxiv : the preprint server for biology2023

Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodies.

Mark M Painter, Timothy S Johnston, Kendall A Lundgreen, Jefferson J S Santos, Juliana S Qin, Rishi R Goel, Sokratis A Apostolidis, Divij Mathew, Bria Fulmer, Justine C Williams and 27 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 6 institutions in 1 country.

Mark M PainterInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Timothy S JohnstonInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Kendall A LundgreenDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Jefferson J S SantosDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Juliana S QinImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Rishi R GoelInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Sokratis A ApostolidisInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Divij MathewInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Bria FulmerInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Justine C WilliamsImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Michelle L McKeagueImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Ajinkya PattekarImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Ahmad GoodeImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Sean NastaImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Amy E BaxterInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Josephine R GilesInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Ashwin N SkellyInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Laura E FelleyDivision of Infectious Disease, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Maura McLaughlinInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Joellen WeaverDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Penn Medicine BioBank
Oliva KuthuruInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Jeanette DoughertyImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Sharon AdamskiImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Sherea LongImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Macy KeeImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Cynthia ClendeninImmune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Ricardo da Silva AntunesCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI); La Jolla, CA, USA.
Alba GrifoniCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI); La Jolla, CA, USA.
Daniela WeiskopfCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI); La Jolla, CA, USA.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI); La Jolla, CA, USA.
Alexander C HuangInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Daniel J RaderDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Scott E HensleyDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Paul BatesDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
Allison R GreenplateInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
E John WherryInstitute for Immunology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
University of Pennsylvania · USTranslational Therapeutics (United States) · USLa Jolla Institute for Immunology · USParker Institute for Cancer Immunotherapy · USNational Institutes of Health · USUniversity of Michigan · US

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007170 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BRASS, LAWRENCE F · 1985 to 2022
$54.0M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HENSLEY, SCOTT · 2021 to 2025
$50.7M
Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
Synergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2015 to 2026
$30.8M
IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1M
Modeling HIV CAR-T cell trafficking and persistence in Non-Human PrimatesU19AI149680 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI RILEY, JAMES L. · 2020 to 2024
$13.2M
Development of vaccines targeting a tick-borne phlebovirusR01AI152236 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BATES, PAUL · 2020 to 2024
$3.0M
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by ToxR01AI155577 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2020 to 2024
$2.7M
Training Program/Rheumatic DiseasesT32AR076951 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI EDWARD M BEHRENS, Peter A Merkel · 2020 to 2026
$2.6M
Cellular and transcriptional control of exhausted CD8 T cells lineage dynamicsR01AI105343 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2014 to 2017
$1.6M
The Penn-StARR Program for Research in ResidencyR38HL143613 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KLEIN, PETER S · 2018 to 2021
$1.4M
NCATS NIH HHS UL1 TR001878NCI NIH HHS K08 CA230157NCI NIH HHS T32 CA009140NHLBI NIH HHS R38 HL143613NIAID NIH HHS 75N93021C00015NIAID NIH HHS P01 AI108545NIAID NIH HHS R01 AI105343NIAID NIH HHS R01 AI152236NIAID NIH HHS R01 AI155577NIAID NIH HHS U19 AI082630NIAID NIH HHS U19 AI149680NIAMS NIH HHS T32 AR076951NIGMS NIH HHS T32 GM007170
6 · The paper itself

Abstract

SARS-CoV-2 infection of vaccinated individuals is increasingly common but rarely results in severe disease, likely due to the enhanced potency and accelerated kinetics of memory immune responses. However, there have been few opportunities to rigorously study early recall responses during human viral infection. To better understand human immune memory and identify potential mediators of lasting vaccine efficacy, we used high-dimensional flow cytometry and SARS-CoV-2 antigen probes to examine immune responses in longitudinal samples from vaccinated individuals infected during the Omicron wave. These studies revealed heightened Spike-specific responses during infection of vaccinated compared to unvaccinated individuals. Spike-specific CD4 T cells and plasmablasts expanded and CD8 T cells were robustly activated during the first week. In contrast, memory B cell activation, neutralizing antibody production, and primary responses to non-Spike antigens occurred during the second week. Collectively, these data demonstrate the functionality of vaccine-primed immune memory and highlight memory T cells as rapid responders during SARS-CoV-2 infection.

Identifiers

PMID36798171
PMCPMC9934532
OpenAlexW4319299309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.